| Description | SBP-3264 is a novel inhibitor of serine/threonine-protein kinases 3 and 4 (STK3 and STK4). |
| In vitro | SBP-3264 specifically inhibited the Hippo signaling pathway in cultured mammalian cells. |
| In vivo | SBP-3264 possessed favorable pharmacokinetic and pharmacodynamic properties in mice. |
| molecular weight | 369.85 |
| Molecular formula | C19H20ClN5O |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 1 mg/ml, Sonication is recommended. |
| References | 1. Nicole Bata, et al. Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia. J Med Chem. 2022 Jan 27;65(2):1352-1369. Letters in Drug Design & Discovery (2014), 11(9), 1119-1123. |